CymaBay Therapeutics Inc.

NASDAQ: CBAYHealthcare / Biotechnology / USA
5.93+0.0200+0.34%Vol 195 8631Y Perf -51.03%
Aug 21st, 2019 16:00
BID5.93 ASK5.94
Open5.98 Previous Close5.91
Pre-Market- After-Trading5.93
 - -%  - -%
Target Price
17.10 
Analyst Rating
Strong Buy 1.20
Potencial %
188.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-/-/- 
Value Ranking
★★ —    -
Insiders Value % 3/6/12M
-/-/-70 
Growth Ranking
★★★ —    -
Insiders Shares Cnt. % 3/6/12M
-/-/-68 
Income Ranking
 —    -
Market Cap (mil)407 
Earnings Rating
Buy
Price Range Ratio 52wk %
12.09 
Earnings Date
7th Aug 2019

Today's Price Range

5.805.98

52wk Range

4.8214.00

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
1.02%
1 Month
-8.77%
3 Months
-51.79%
6 Months
-47.71%
1 Year
-51.03%
3 Years
156.71%
5 Years
18.13%
10 Years
-

Name / TickerPriceChg.Chg.%
CBAY5.930.02000.34
AAPL212.642.28001.08
GOOG1 191.258.56000.72
MSFT138.791.53001.11
XOM69.720.69001.00
WFC45.000.32000.72
JNJ131.530.93000.71
FB183.55-0.2600-0.14
GE8.16-0.2200-2.63
JPM107.610.30000.28
Earnings HistoryEstimateReportedSurprise %
Q02 2019-0.37-0.355.41
Q01 2019-0.34-0.37-8.82
Q04 2018-0.36-0.3211.11
Q03 2018-0.30-0.34-13.33
Q02 2018-0.25-0.30-20.00
Q01 2018-0.14-0.32-128.57
Q04 2017-0.17-0.1135.29
Q03 2017-0.19-0.21-10.53
Earnings Per EndEstimateRevision %Trend
9/2019 QR-0.370.00-
12/2019 QR-0.390.00-
12/2019 FY-1.470.68Positive
12/2020 FY-1.68-6.33Negative
Next Report Date-
Estimated EPS Next Report-0.37
Estimates Count8
EPS Growth Next 5 Years %-
Volume Overview
Volume195 863
Shares Outstanding (in ths.)68 701
Trades Count1 870
Dollar Volume1 978 889
Avg. Volume946 499
Avg. Weekly Volume365 417
Avg. Monthly Volume607 924
Avg. Quarterly Volume1 311 801
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
9 (90.00 %)
9 (90.00 %)
8 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
1 (10.00 %)
Hold
1 (10.00 %)
1 (10.00 %)
1 (10.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
RatingStrong Buy
1.20
Strong Buy
1.20
Strong Buy
1.30

CymaBay Therapeutics Inc.

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

CEO: Sujal Shah

Teplephone: +1 510 293-8800

Address: 7575 Gateway Boulevard, Newark 94560, CA, USA

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

68%32%

News